ProfoundBio, led by former Seagen executives, raises $55M Series A to advance ADCs and T‑cell engager programs

ProfoundBio, a biotech headquartered in Woodinville, Washington, and Suzhou, China, raised $55 million in a Series A to advance preclinical anti-cancer programs focused on antibody-drug conjugates and a T‑cell engager. The company is led by former Seagen executives and plans multiple IND submissions in 2022 and beyond.